Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension

被引:2
|
作者
Becker, Andreas [1 ]
Krebs-Brown, Axel [1 ]
Vetter, Claudia [1 ]
Reuter, Tanja [1 ]
Rodriguez-Gutierrez, Almudena [2 ,3 ]
You, Xiaoli [4 ]
Lissy, Michael [5 ]
机构
[1] Healthcare Business Merck KGaA, Frankfurter Str 250,F135-003, D-64293 Darmstadt, Germany
[2] SLU, Merck, Madrid, Spain
[3] Merck KGaA, Darmstadt, Germany
[4] EMD Serono, Billerica, MA USA
[5] NUVISAN GmbH, Neu Ulm, Germany
来源
关键词
CRYO-EM STRUCTURE; PK; ATM;
D O I
10.1111/cts.13657
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Peposertib is an orally administered inhibitor of DNA-dependent protein kinase. We evaluated the effect of food on its pharmacokinetics, and examined the pharmacokinetics of an oral suspension (OS) of disintegrated tablets, in a phase I, open-label, crossover three-period study (NCT04702698). Twelve healthy volunteers were randomized to one of six treatment sequences. They received a single dose of peposertib 100 mg as film-coated tablets under fasted or fed conditions ("tablet fasted" or "tablet fed") or as an OS under fasted conditions ("OS fasted"), with washout between treatments. Using healthy volunteers was possible because, despite its mechanism of action being suppression of DNA repair, peposertib has shown no genotoxic effect in animals. A mild food effect was observed with peposertib tablets. Fed-to-fasted ratios were: area under the curve from time 0 to time t (AUC(0-t)), 123.81% (90% confidence interval [CI]: 108.04, 141.87%); AUC from zero to infinity (AUC(0-infinity)), 110.28% (90% CI 100.71, 120.77%); and maximum concentration (C-max) 104.47% (90% CI: 79.15, 137.90%). C-max was delayed under fed conditions (median time to maximum concentration [T-max] was 3.5 h [tablet fed] vs. 1 h [tablet fasted]). OS-to-tablet (fasted) ratios were: AUC(0-t), 124.83% (90% CI: 111.50%, 139.76%); AUC(0-infinity), 119.05% (90% CI: 104.47, 135.67%); and C-max 173.29% (90% CI: 135.78, 221.16%). Median T-max was 0.5 h (OS fasted) versus 1 h (tablet). All treatments were well-tolerated in healthy volunteers. Peposertib tablets can be taken with or without food; if combined with chemotherapy or radiotherapy, the delay in C-max must be considered to optimize the chemo- or radiosensitizing effect. The peposertib OS form represents an alternative route of administration in patients with specific cancers causing dysphagia. However, the OS form should be part of future dose optimization strategies in relevant settings.
引用
收藏
页码:2628 / 2639
页数:12
相关论文
共 50 条
  • [1] A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers
    Wu, Min
    Li, Xiaojiao
    Sun, Jixuan
    Chen, Hong
    Ding, Yanhua
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (04) : 503 - 508
  • [2] THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ICLEPERTIN (BI 425809), A GLYCINE TRANSPORTER 1 INHIBITOR, IN HEALTHY VOLUNTEERS: A PHASE I OPEN-LABEL, RANDOMIZED, CROSSOVER TRIAL
    Harada, Akiko
    Madari, Shilpa
    Jungnik, Arvid
    Breithaupt-Groegler, Kerstin
    Hohl, Kathrin
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i360 - i361
  • [3] A phase I single-rising-dose study of oral BI 1358894 in healthy male volunteers: safety, pharmacokinetics and food effect
    Fuertig, R.
    Goettel, M.
    Hoefler, J.
    Sharma, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S256 - S257
  • [4] Pharmacokinetics of panomifene in healthy volunteers at phase I/a study
    ErdelyiToth, V
    Gyergyay, F
    Szamel, I
    Pap, E
    Kralovanszky, J
    Bojti, E
    Csorgo, M
    Drabant, S
    Klebovich, I
    ANTI-CANCER DRUGS, 1997, 8 (06) : 603 - 609
  • [5] A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension
    Li, Yan
    Liu, Liangang
    Huang, Lian
    Wang, Xiaomin
    Hoffmann, Matthew
    Reyes, Josephine
    Palmisano, Maria
    Zhou, Simon
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 : 1089 - 1099
  • [6] The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers
    S. El Messaoudi
    F. G. Russel
    A. Colbers
    C. C. J. G. Bandell
    P. H. H. van den Broek
    D. M. Burger
    G. A. Rongen
    N. P. Riksen
    European Journal of Clinical Pharmacology, 2016, 72 : 725 - 730
  • [7] The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers
    El Messaoudi, S.
    Russel, F. G.
    Colbers, A.
    Bandell, C. C. J. G.
    van den Broek, P. H. H.
    Burger, D. M.
    Rongen, G. A.
    Riksen, N. P.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (06) : 725 - 730
  • [8] A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers
    Cabanis, Marie-Jose
    Nicolas, Olivier
    Vitse, Olivier
    Jan, Christelle
    Brun, Priscilla
    Soubayrol, Patrick
    Smith, William B.
    Turner, Timothy J.
    Krupka, Emmanuel
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (02):
  • [9] Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers
    Mendell, Jeanne
    Tachibana, Masaya
    Shi, Minggao
    Kunitada, Satoshi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (05): : 687 - 694
  • [10] The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
    Tugnait, Meera
    Gupta, Neeraj
    Hanley, Michael J.
    Venkatakrishnan, Karthik
    Sonnichsen, Daryl
    Kerstein, David
    Dorer, David J.
    Narasimhan, Narayana
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (06): : 734 - 741